Deutsch English Français

Contact

EP2503992

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...

Extract from the Register of European Patents

EP About this file: EP2503992

EP2503992 - FORMULATIONS OF BISPHOSPHONATES AND VITAMIN D SUITABLE FOR INTERMITTENT INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION [Right-click to bookmark this link]
Status	No opposition filed within time limit Status updated on 24.02.2017 Database last updated on 26.03.2026
Most recent event Tooltip	12.10.2018	Lapse of the patent in a contracting state New state(s): AL	published on 14.11.2018 [2018/46]
Applicant(s)	For all designated states Romano, Paolo Via S. Anguissola, 12 20146 Milano / IT
	For all designated states Bruzzese, Tiberio Via Giuseppe Frua, 21/6 20146 Milan / IT
	[2012/40]
Inventor(s)	01 / BRUZZESE, Tiberio Via Giuseppe Frua, 21/6 I-20146 Milano / IT
	[2012/40]
Representative(s)	Ferreccio, Rinaldo Botti & Ferrari S.p.A. Via Cappellini, 11 20124 Milano / IT
	[N/P]
Former [2012/40]	Ferreccio, Rinaldo Botti & Ferrari S.r.l. Via Cappellini, 11 20124 Milano / IT
Application number, filing date	10794865.5	25.11.2010
	[2016/16]
	WO2010EP07140
Priority number, date	IT2009MI02083	26.11.2009 Original published format: IT MI20092083
	[2012/40]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO2011063952
	Date:	03.06.2011
	Language:	EN
	[2011/22]
	Type:	A1 Application with search report
	No.:	EP2503992
	Date:	03.10.2012
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 03.06.2011 takes the place of the publication of the European patent application.
	[2012/40]
	Type:	B1 Patent specification
	No.:	EP2503992
	Date:	20.04.2016
	Language:	EN
	[2016/16]
Search report(s)	International search report - published on:	EP	03.06.2011
Classification	IPC:	A61K9/107, A61K47/14, A61K9/00	[2012/40]
	CPC:	A61K47/46 (EP,US); A61K9/0019 (EP,US); A61K9/107 (EP,US); A61P19/08 (EP); A61P23/02 (EP); A61P35/00 (EP)
Designated contracting states	AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2012/40]
Extension states	BA	Not yet paid
	ME	Not yet paid
Title	German:	FORMULIERUNGEN AUS BISPHOSPHONATEN UND VITAMIN D FÜR INTERMITTIERENDE INTRAMUSKULÄRE UND SUBKUTANE VERABREICHUNG	[2012/40]
	English:	FORMULATIONS OF BISPHOSPHONATES AND VITAMIN D SUITABLE FOR INTERMITTENT INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION	[2012/40]
	French:	FORMULATIONS DE BISPHOSPHONATES ET DE VITAMINE D SE PRÊTANT À UNE ADMINISTRATION INTERMITTENTE PAR VOIE INTRAMUSCULAIRE ET SOUS-CUTANÉE	[2012/40]
Entry into regional phase	26.06.2012	National basic fee paid
	26.06.2012	Designation fee(s) paid
	26.06.2012	Examination fee paid
Examination procedure	26.06.2012	Amendment by applicant (claims and/or description)
	26.06.2012	Examination requested [2012/40]
	25.03.2014	Despatch of a communication from the examining division (Time limit: M04)
	12.06.2014	Reply to a communication from the examining division
	02.11.2015	Communication of intention to grant the patent
	01.03.2016	Fee for grant paid
	01.03.2016	Fee for publishing/printing paid
	01.03.2016	Receipt of the translation of the claim(s)
Divisional application(s)	The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 25.03.2014
Opposition(s)	23.01.2017	No opposition filed within time limit [2017/13]
Fees paid	Renewal fee
	04.10.2012	Renewal fee patent year 03
	29.11.2013	Renewal fee patent year 04
	25.11.2014	Renewal fee patent year 05
	26.11.2015	Renewal fee patent year 06
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition Tooltip	HU	25.11.2010
	AL	20.04.2016
	AT	20.04.2016
	BE	20.04.2016
	BG	20.04.2016
	CY	20.04.2016
	CZ	20.04.2016
	DK	20.04.2016
	EE	20.04.2016
	FI	20.04.2016
	HR	20.04.2016
	IS	20.04.2016
	IT	20.04.2016
	LT	20.04.2016
	LV	20.04.2016
	MC	20.04.2016
	MK	20.04.2016
	PL	20.04.2016
	RO	20.04.2016
	RS	20.04.2016
	SE	20.04.2016
	SI	20.04.2016
	SK	20.04.2016
	SM	20.04.2016
	TR	20.04.2016
	NO	20.07.2016
	GR	21.07.2016
	PT	22.08.2016
	IE	25.11.2016
	MT	25.11.2016
	LU	30.11.2016
	[2018/46]
Former [2018/43]	HU	25.11.2010
	AT	20.04.2016
	BE	20.04.2016
	BG	20.04.2016
	CY	20.04.2016
	CZ	20.04.2016
	DK	20.04.2016
	EE	20.04.2016
	FI	20.04.2016
	HR	20.04.2016
	IS	20.04.2016
	IT	20.04.2016
	LT	20.04.2016
	LV	20.04.2016
	MC	20.04.2016
	MK	20.04.2016
	PL	20.04.2016
	RO	20.04.2016
	RS	20.04.2016
	SE	20.04.2016
	SI	20.04.2016
	SK	20.04.2016
	SM	20.04.2016
	TR	20.04.2016
	NO	20.07.2016
	GR	21.07.2016
	PT	22.08.2016
	IE	25.11.2016
	MT	25.11.2016
	LU	30.11.2016
Former [2018/38]	HU	25.11.2010
	AT	20.04.2016
	BE	20.04.2016
	BG	20.04.2016
	CY	20.04.2016
	CZ	20.04.2016
	DK	20.04.2016
	EE	20.04.2016
	FI	20.04.2016
	HR	20.04.2016
	IS	20.04.2016
	IT	20.04.2016
	LT	20.04.2016
	LV	20.04.2016
	MC	20.04.2016
	MK	20.04.2016
	PL	20.04.2016
	RO	20.04.2016
	RS	20.04.2016
	SE	20.04.2016
	SI	20.04.2016
	SK	20.04.2016
	SM	20.04.2016
	TR	20.04.2016
	NO	20.07.2016
	GR	21.07.2016
	PT	22.08.2016
	IE	25.11.2016
	LU	30.11.2016
Former [2018/30]	HU	25.11.2010
	AT	20.04.2016
	BE	20.04.2016
	CY	20.04.2016
	CZ	20.04.2016
	DK	20.04.2016
	EE	20.04.2016
	FI	20.04.2016
	HR	20.04.2016
	IS	20.04.2016
	IT	20.04.2016
	LT	20.04.2016
	LV	20.04.2016
	MC	20.04.2016
	MK	20.04.2016
	PL	20.04.2016
	RO	20.04.2016
	RS	20.04.2016
	SE	20.04.2016
	SI	20.04.2016
	SK	20.04.2016
	SM	20.04.2016
	TR	20.04.2016
	NO	20.07.2016
	GR	21.07.2016
	PT	22.08.2016
	IE	25.11.2016
	LU	30.11.2016
Former [2018/29]	HU	25.11.2010
	AT	20.04.2016
	BE	20.04.2016
	CY	20.04.2016
	CZ	20.04.2016
	DK	20.04.2016
	EE	20.04.2016
	FI	20.04.2016
	HR	20.04.2016
	IT	20.04.2016
	LT	20.04.2016
	LV	20.04.2016
	MC	20.04.2016
	MK	20.04.2016
	PL	20.04.2016
	RO	20.04.2016
	RS	20.04.2016
	SE	20.04.2016
	SI	20.04.2016
	SK	20.04.2016
	SM	20.04.2016
	TR	20.04.2016
	NO	20.07.2016
	GR	21.07.2016
	PT	22.08.2016
	IE	25.11.2016
	LU	30.11.2016
Former [2018/28]	HU	25.11.2010
	AT	20.04.2016
	BE	20.04.2016
	CY	20.04.2016
	CZ	20.04.2016
	DK	20.04.2016
	EE	20.04.2016
	FI	20.04.2016
	HR	20.04.2016
	IT	20.04.2016
	LT	20.04.2016
	LV	20.04.2016
	MC	20.04.2016
	MK	20.04.2016
	PL	20.04.2016
	RO	20.04.2016
	RS	20.04.2016
	SE	20.04.2016
	SI	20.04.2016
	SK	20.04.2016
	SM	20.04.2016
	NO	20.07.2016
	GR	21.07.2016
	PT	22.08.2016
	IE	25.11.2016
	LU	30.11.2016
Former [2017/51]	AT	20.04.2016
	BE	20.04.2016
	CZ	20.04.2016
	DK	20.04.2016
	EE	20.04.2016
	FI	20.04.2016
	HR	20.04.2016
	IT	20.04.2016
	LT	20.04.2016
	LV	20.04.2016
	PL	20.04.2016
	RO	20.04.2016
	RS	20.04.2016
	SE	20.04.2016
	SI	20.04.2016
	SK	20.04.2016
	SM	20.04.2016
	NO	20.07.2016
	GR	21.07.2016
	PT	22.08.2016
	IE	25.11.2016
	LU	30.11.2016
Former [2017/48]	AT	20.04.2016
	BE	20.04.2016
	CZ	20.04.2016
	DK	20.04.2016
	EE	20.04.2016
	FI	20.04.2016
	HR	20.04.2016
	IT	20.04.2016
	LT	20.04.2016
	LV	20.04.2016
	PL	20.04.2016
	RO	20.04.2016
	RS	20.04.2016
	SE	20.04.2016
	SI	20.04.2016
	SK	20.04.2016
	SM	20.04.2016
	NO	20.07.2016
	GR	21.07.2016
	PT	22.08.2016
	LU	30.11.2016
Former [2017/37]	AT	20.04.2016
	BE	20.04.2016
	CZ	20.04.2016
	DK	20.04.2016
	EE	20.04.2016
	FI	20.04.2016
	HR	20.04.2016
	IT	20.04.2016
	LT	20.04.2016
	LV	20.04.2016
	PL	20.04.2016
	RO	20.04.2016
	RS	20.04.2016
	SE	20.04.2016
	SI	20.04.2016
	SK	20.04.2016
	SM	20.04.2016
	NO	20.07.2016
	GR	21.07.2016
	PT	22.08.2016
Former [2017/11]	AT	20.04.2016
	BE	20.04.2016
	CZ	20.04.2016
	DK	20.04.2016
	EE	20.04.2016
	FI	20.04.2016
	HR	20.04.2016
	IT	20.04.2016
	LT	20.04.2016
	LV	20.04.2016
	PL	20.04.2016
	RO	20.04.2016
	RS	20.04.2016
	SE	20.04.2016
	SK	20.04.2016
	SM	20.04.2016
	NO	20.07.2016
	GR	21.07.2016
	PT	22.08.2016
Former [2017/10]	AT	20.04.2016
	BE	20.04.2016
	CZ	20.04.2016
	DK	20.04.2016
	EE	20.04.2016
	FI	20.04.2016
	HR	20.04.2016
	IT	20.04.2016
	LT	20.04.2016
	LV	20.04.2016
	PL	20.04.2016
	RO	20.04.2016
	RS	20.04.2016
	SE	20.04.2016
	SK	20.04.2016
	NO	20.07.2016
	GR	21.07.2016
	PT	22.08.2016
Former [2017/09]	AT	20.04.2016
	BE	20.04.2016
	CZ	20.04.2016
	DK	20.04.2016
	EE	20.04.2016
	FI	20.04.2016
	HR	20.04.2016
	IT	20.04.2016
	LT	20.04.2016
	LV	20.04.2016
	PL	20.04.2016
	RO	20.04.2016
	RS	20.04.2016
	SE	20.04.2016
	NO	20.07.2016
	GR	21.07.2016
	PT	22.08.2016
Former [2017/07]	AT	20.04.2016
	BE	20.04.2016
	DK	20.04.2016
	FI	20.04.2016
	HR	20.04.2016
	IT	20.04.2016
	LT	20.04.2016
	LV	20.04.2016
	PL	20.04.2016
	RS	20.04.2016
	SE	20.04.2016
	NO	20.07.2016
	GR	21.07.2016
	PT	22.08.2016
Former [2017/03]	AT	20.04.2016
	BE	20.04.2016
	FI	20.04.2016
	HR	20.04.2016
	IT	20.04.2016
	LT	20.04.2016
	LV	20.04.2016
	PL	20.04.2016
	RS	20.04.2016
	SE	20.04.2016
	NO	20.07.2016
	GR	21.07.2016
	PT	22.08.2016
Former [2016/52]	AT	20.04.2016
	FI	20.04.2016
	HR	20.04.2016
	LT	20.04.2016
	LV	20.04.2016
	PL	20.04.2016
	RS	20.04.2016
	SE	20.04.2016
	NO	20.07.2016
	GR	21.07.2016
	PT	22.08.2016
Former [2016/51]	AT	20.04.2016
	FI	20.04.2016
	HR	20.04.2016
	LT	20.04.2016
	LV	20.04.2016
	PL	20.04.2016
	RS	20.04.2016
	NO	20.07.2016
	GR	21.07.2016
	PT	22.08.2016
Former [2016/50]	AT	20.04.2016
	FI	20.04.2016
	HR	20.04.2016
	LT	20.04.2016
	LV	20.04.2016
	PL	20.04.2016
	RS	20.04.2016
	NO	20.07.2016
Former [2016/49]	FI	20.04.2016
	LT	20.04.2016
	PL	20.04.2016
	NO	20.07.2016
Former [2016/46]	LT	20.04.2016
	NO	20.07.2016
Cited in	by applicant	FLEISH H ET AL., AM J PHYSIOL, vol. 203, 1962, pages 671
		FLEISH H ET AL., SCIENCE, vol. 165, 1969, pages 1262
		ROSEN JD ET AL., DRUGS, vol. 51, 1996, pages 537
		MAALOUF NM ET AL., ENDOCRINE PRACT, vol. 12, 2006, pages 48
		ALTUNDAG 0 ET AL., J CLIN ONCOL, vol. 22, 2004, pages 2035
		PETER R ET AL., BMJ, vol. 328, 2004, pages 335
		DROGUE T ET AL., INDIAN J MED SCI, vol. 59, 2005, pages 542
		PERAZZELLA MA ET AL., KIDNEY INTERNATIONAL, vol. 74, 2008, pages 1385
		DIEL IJ ET AL., J SUPPORT ONCOL, vol. 5, 2007, pages 475
		WALLACE JL ET AL., ALIMENT PHARMACOL THERE, vol. 13, 1999, pages 1675
		KANATSU K, J. GASTROENT. AND HEPATOL., vol. 19, 2004, pages 512
		EZRA A ET AL., ADVAN DRUG DELIV REVIEWS, vol. 42, 2000, pages 175
		HYLDSTRUP L ET AL., CALCIFICATION TISSUE INT, vol. 53, 1993, pages 297
		MITCHELL DY ET AL., PHARMACEUTICAL RESEARCH, vol. 18, 2001, pages 166
		FOGELMAN I ET AL., CLIN ENDOCRINOL, vol. 24, 1986, pages 57
		GERTZ B ET AL., OSTEOPOROSIS INT, vol. 53, 1993, pages 513
		DALEY-YATES PT ET AL., CALCIF TISSUE INT, vol. 49, 1991, pages 433
		RECKER RR, TOXICOL APPL PHARMACOL, vol. 24, 1973, pages 580
		PLASKER GL ET AL., DRUGS, vol. 47, 1994, pages 945
		LAITINEN K ET AL., BONE, vol. 27, 2000, pages 293
		DODWELL DJ ET AL., BR.J. CANCER, vol. 61, 1990, pages 123
		HARINEK HI ET AL., BRIT J. RES. ED, vol. 295, 1987, pages 1301
		FITTON A ET AL., DRUGS, vol. 41, 1991, pages 289
		DEGROEN PC ET AL., NEW ENGL. J. MED, vol. 335, 1996, pages 1016
		ROSSINI ET AL., OSTEOPOROSIS INT., vol. 17, 2006, pages 914
		SARTORI L ET AL., AGING CLIN. EXP RES, vol. 15, 2003, pages 271
		REGINSTER JY ET AL., DRUGS AGING, vol. 24, 2007, pages 351
		EASTELL R ET AL., J CLIN ENDOCRINOL METAB., vol. 94, 2009, pages 3215
		LAUREN L ET AL., PHARMACOL TOXICOL, vol. 69, 1991, pages 365
		MUNTONI E ET AL., J. CHROMATOGR B ANALYTE TECHNOL BIOMED LIFE SCI, vol. 5, 2004, pages 133
		ROSSINI, BONE, vol. 24, 1999, pages 125
		BROWN ET AL., AM J PHYSIOL, vol. 277, 1999, pages 157
		STROUD ML ET AL., AUSTRALIAN FAMILY PHYSICIAN, vol. 37, 2008, pages 1002
		SUDA T, J OF CELLULAR BIOCHEMISTRY, vol. 88, 2003, pages 259
		IKEDA K, ENDOCRINE JOURNAL, vol. 54, 2007, pages 1
		THOMAS MK ET AL., N ENG J MED, vol. 338, 1998, pages 777
		LIPS P, ENDOCRINE REV, vol. 22, 2001, pages 47
		HOLICK MF, AM J CLINNUTR, vol. 60, 1994, pages 619
		PAPADIMITROPOULOS E ET AL., ENDOCRINE REV, vol. 23, 2002, pages 560
		BISCHOFF-FERRARI HA ET AL., JAMA, vol. 46, 2005, pages 676
		FUJIOKA T ET AL., J UROL, vol. 160, 1998, pages 247
		DALHOFF K ET AL., BR J CANCER, vol. 89, 2003, pages 252
		TRUMP DL ET AL., CANCER, vol. 106, 2006, pages 2136
		GARLAND C ET AL., LANCET, vol. 1, 1985, pages 307
		SCHWARTZ GG ET AL., CLIN CANCER RES, vol. 11, 2005, pages 8680
		BISCHOFF -FERRARI HA ET AL., AM J CLIN NUTR, vol. 84, 2006, pages 18
		PM WHYTE ET AL., J CLIN ENDOCRINOL. METABOL, vol. 48, 1979, pages 906
		ROMAGNOLI E ET AL., J CLIN ENDOCRINOL METAB., vol. 93, 2008, pages 3015
		KOSTER JC ET AL., EUR J CLIN PHARMACO, vol. 51, 1996, pages 145
		DEAN ET AL., BMC MUSCULOSKELETAL DISORDERS, vol. 8, 2007, pages 3
		ALLAIN TJ ET AL., RHEUMATOLOGY, vol. 45, 2006, pages 487
		MARTINEZ ME ET AL., CALCIF. TISSUE INT., vol. 61, 1997, pages 148
		BILLE N ET AL., NORD VET MED 1976, vol. 28, 1991, pages 496
		LAUREN ET AL., PHARMACOLOGY & TOXICOLOGY, vol. 69, 1991, pages 356

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.